New Delhi, June 10 (UNI) Leading voices from the pharmaceutical industry, biotech start-ups, funding agencies such as BIRAC, and premier academic institutions convened on Tuesday to explore new strategies for accelerating monoclonal antibody (mAb) therapies in India. Such a therapy uses antibodies, made in a lab, to target and treat specific diseases, including cancer.

The symposium, organised by the Translational Health Science and Technology Institute (THSTI), highlighted India’s rapidly growing biopharmaceutical sector and noted the vast potential for indigenous innovation in the development of mAb therapies—critical tools in precision medicine.